MedTech Europe has expressed strong support for proposed changes to the In Vitro Diagnostic Regulation (IVDR), advocating for enhancements in specific areas to optimize regulatory processes.
The trade group categorized the proposed IVDR changes into “welcome” and “strengthen” categories, indicating a positive reception overall. A key highlight is the European Commission's initiative for proportionate oversight of low-risk devices, which MedTech Europe views as a necessary adjustment to current regulations that apply uniform requirements across low-risk in vitro diagnostic (IVD) products. They urge clearer legal provisions for routine procedures to prevent unnecessary burdens on established practices like blood draws.
Moreover, MedTech Europe emphasizes the importance of maintaining CE-marked devices as the standard for regulatory compliance. They caution that expanding health institutions' ability to use their own tests could lead to a fragmented regulatory environment, potentially undermining the integrity of CE-marked products. The group advocates for limiting these health institution tests to scenarios where no CE-marked alternatives exist.
On the topic of orphan IVDs, MedTech Europe supports a revised definition that aligns with the orphan drug threshold, proposing a limit of 5 in 10,000 individuals affected, rather than the current 1 in 12,000. This change is seen as crucial for ensuring the availability of essential diagnostic tests that support timely medical interventions.
This proactive stance by MedTech Europe not only reflects the industry’s commitment to regulatory efficiency but also highlights the ongoing need for a balanced approach in the evolving landscape of medical technology regulation. As the industry continues to adapt, the implications of these proposed changes could significantly influence the accessibility and reliability of diagnostic tools in healthcare.